focus -WSS

focus

author：explore 2025-09-06 01:50:44 - browse：386

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Churchill Downs extends trainer Bob Baffert's ban through 2024

focus

knowledge

WSS

Liver decline slowed by off

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

Questions and answers about ramping up H5N1 bird flu vaccine

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Wikipedia

focus

leisure time

Apple is now the first public company to be valued at $3 trillion

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Cue Health, Covid

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bird flu surveillance in wastewater gets boost from consortium

DIEP, the 'gold standard' of breast reconstruction, is under threat

Elon Musk announces 'temporary limits' for reading Twitter posts

In Memoriam: Notable people who died in 2023

Making the case for fair compensation in clinical trials

explore

Trump pressured former Arizona governor to overturn 2020 election results: Sources

Cue Health, Covid

Reports of telehealth's death have been greatly exaggerated

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Russians and Belarusians back at Wimbledon as war in Ukraine continues

focus

knowledge

hotspot

focus